Potassium channel activators in the management of ischaemic heart disease: a focus on nicorandil.
The treatment of angina pectoris continues to pose challenges. Novel new compounds are a rarity, but the potassium channel activators represent a new class of drugs with novel mechanisms of action. Nicorandil will be the first available potassium channel modulator for treatment of angina, and the following review assesses its clinical potential.
Purcell
H
H
Royal Brompton National Heart & Lung Hospital, London.
Fox
K
K
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020108:Nicorandil; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D008996:Monoamine Oxidase Inhibitors; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil